Stratton P, Battiwalla M, Tian X, et al. - A prospective, open-label phase-1 study was designed to ascertain the safety and immunogenicity of the quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) in clinically stable women post–allogeneic transplant compared with female healthy volunteers. This research was carried out in a government clinical research hospital and included clinically stable women posttransplant who were or were not receiving immunosuppressive therapy correlated with healthy female volunteers age 18 to 50 years who were followed up or a year after first taking quadrivalent HPV vaccination between June 2, 2010, until July 19, 2016. Researchers assessed anti-HPV-6, -11, -16, and -18–specific antibody responses using L1 virus-like particle enzyme-linked immunosorbent assay in serum before (day 1) and at months 7 and 12 postvaccination. This study ascertained anti-HPV-16 and -18 neutralization titers using a pseudovirion-based neutralization assay. IT was noted that treatment with the HPV vaccination was followed by strong, functionally active antibody responses against vaccine-related HPV types and no serious adverse events. The data imply that HPV vaccination may be safely administered to women posttransplant to potentially decrease HPV infection and related neoplasia.